NDT Plus Advance Access published online on May 1, 2008
NDT Plus, doi:10.1093/ndtplus/sfn044
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Reversible Fanconi syndrome due to lenalidomide
1 Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
3 Renal Division, Weill Medical College of Cornell University, New York, NY, USA
Correspondence: Ilya G. Glezerman, Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. E-mail: glezermi@mskcc.org
Key Words: Fanconi syndrome lenalidomide multiple myeloma
Received for publication February 6, 2008. Accepted for publication April 2, 2008.
| The first 10% of the full text of this article appears below. |
| Background |
|---|
Renal disease is a common manifestation of multiple myeloma (MM), a plasma cell dyscrasia. The spectrum of renal disease includes cast nephropathy, light chain amyloidosis, monoclonal Ig deposition disease and cryoglobulinemic as well as proliferative glomerulonephritis. Patients most often present with abnormal renal function and proteinuria. Occasionally, patients also present with renal tubular dysfunction such as acidification and concentration defects and rarely with Fanconi syndrome (FS) [1]. FS is a proximal renal tubular dysfunction characterized by renal glucosuria, generalized aminoaciduria and hypophosphatemia. Other manifestations may include defect of bicarbonate reabsorption, renal acidification, urinary concentration, potassium as well as sodium and calcium reabsorption [2].
Kidney biopsy in patients with FS due to MM
| Case report |
|---|
| Discussion |
|---|